Resverlogix Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 17

Employees

  • Stock Symbol
  • RVX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.05
  • (As of Friday Closing)

Resverlogix General Information

Description

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4820 Richard Road Southwest
  • Suite 300
  • Calgary, Alberta T3E 6L1
  • Canada
+1 (403)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
TSE
Vertical(s)
Corporate Office
  • 4820 Richard Road Southwest
  • Suite 300
  • Calgary, Alberta T3E 6L1
  • Canada
+1 (403)

Resverlogix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Resverlogix Stock Performance

As of 13-Nov-2026, Resverlogix’s stock price is $0.05. Its current market cap is $18.1M with 344M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.05 $0.05 $0.04 - $0.11 $18.1M 344M 30.4K -$0.03

Resverlogix Financials Summary

As of 30-Jun-2026, Resverlogix has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 93,540 95,916 72,137 74,980
Revenue 0 0 0 0
EBITDA (5,462) (3,071) (4,223) (14,180)
Net Income (10,690) (7,767) (7,635) (16,741)
Total Assets 8,257 7,948 7,344 6,565
Total Debt 21,148 20,798 16,470 9,910
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Resverlogix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Resverlogix‘s full profile, request access.

Request a free trial

Resverlogix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class
Biotechnology
Calgary, Canada
17 As of 2025

Plymouth Meeting, PA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Resverlogix Competitors (120)

One of Resverlogix’s 120 competitors is Harmony Biosciences Holdings, a Formerly VC-backed company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harmony Biosciences Holdings Formerly VC-backed Plymouth Meeting, PA
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
Akari Therapeutics Formerly VC-backed London, United Kingdom
RedHill Biopharma Formerly VC-backed Raleigh, NC
Omeros Formerly VC-backed Seattle, WA
You’re viewing 5 of 120 competitors. Get the full list »

Resverlogix Patents

Resverlogix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021368618-A1 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Active 30-Oct-2020
AU-2021368618-A9 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Active 30-Oct-2020
AU-2021368618-B2 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Active 30-Oct-2020
CA-3197706-A1 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Pending 30-Oct-2020
EP-4236955-A1 Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor Pending 30-Oct-2020 A61K31/517
To view Resverlogix’s complete patent history, request access »

Resverlogix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Resverlogix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Resverlogix‘s full profile, request access.

Request a free trial

Resverlogix Investments (1)

Resverlogix’s most recent deal was a Early Stage VC with EOS Technical Holdings for . The deal was made on 04-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EOS Technical Holdings 04-Jan-2024 Early Stage VC Business/Productivity Software
To view Resverlogix’s complete investments history, request access »

Resverlogix ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Resverlogix’s complete esg history, request access »

Resverlogix FAQs

  • When was Resverlogix founded?

    Resverlogix was founded in 2001.

  • Where is Resverlogix headquartered?

    Resverlogix is headquartered in Calgary, Canada.

  • What is the size of Resverlogix?

    Resverlogix has 17 total employees.

  • What industry is Resverlogix in?

    Resverlogix’s primary industry is Biotechnology.

  • Is Resverlogix a private or public company?

    Resverlogix is a Public company.

  • What is Resverlogix’s stock symbol?

    The ticker symbol for Resverlogix is RVX.

  • What is the current stock price of Resverlogix?

    As of 13-Nov-2026 the stock price of Resverlogix is $0.05.

  • What is the current market cap of Resverlogix?

    The current market capitalization of Resverlogix is $18.1M.

  • Who are Resverlogix’s competitors?

    Harmony Biosciences Holdings, Apellis Pharmaceuticals, Akari Therapeutics, RedHill Biopharma, and Omeros are some of the 120 competitors of Resverlogix.

  • What is Resverlogix’s annual earnings per share (EPS)?

    Resverlogix’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process